GSK, which already makes drugs in Kenya, Nigeria and South Africa, is now looking at sites for additional facilities in countries including Ghana, Ethiopia and Rwanda, a company spokeswoman said.

South Africa generic drugmaker Aspen Pharmacare Holdings Ltd (APNJ.J) has teamed up with shareholder GlaxoSmithKline Plc (GSK) (GSK.L) to extend its presence in Japan, a lucrative market for low ...

GSK already has manufacturing plants in Nigeria, Kenya and South Africa. It also is looking at its supply chain to find ways to get more medicines to rural areas that can be difficult to reach.

GSK is teaming up with the U.K. and South African Medical Research Councils in a $8.07 million collaboration aimed at supporting research into noncommunicable diseases in Africa.

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Business News of Wednesday, 2 April 2014. Source: GSK 2014-04-02 GSK announces new strategic investments in Africa ...

GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a “close relationship” with the South African company. GSK is selling 28.2 million shares in Aspen, ...

GlaxoSmithKline will spend £100 million on a handful of plants in Africa as part of a campaign to help African countries build the facilities and know-how to manufacture the drugs they need at ...

South Africa's biggest generic drug maker Aspen Pharmacare said on Thursday talks with Britain's GlaxoSmithKline about its $700 bid for drugs and a factory continues.

South African pharmaceuticals company Aspen Group will buy GlaxoSmithKline’s thrombosis brands Arixtra and Fraxiparine and their French manufacturing base for £700m in cash, as Aspen – a ...

GlaxoSmithKline has agreed to sell about a third of its stake in South Africa's Aspen Pharmacare, banking about £425 million in the process. GlaxoSmithKline has agreed to sell about a third of its ...

South Africa's Aspen Pharmacare <APNJ.J> said on Monday it has finalized the acquisition of medicines from GlaxoSmithKline <GSK.L> for 163.8 million pounds ($263 million).